Literature DB >> 25614418

Benefit of anticoagulation unlikely in patients with atrial fibrillation and a CHA2DS2-VASc score of 1.

Leif Friberg1, Mika Skeppholm2, Andreas Terént3.   

Abstract

BACKGROUND: Patients with atrial fibrillation (AF) and ≥1 point on the stroke risk scheme CHA2DS2-VASc (congestive heart failure, hypertension, age ≥75 years, diabetes mellitus, stroke/transient ischemic attack, vascular disease, age 65-74 years, sex category) are considered at increased risk for future stroke, but the risk associated with a score of 1 differs markedly between studies.
OBJECTIVES: The goal of this study was to assess AF-related stroke risk among patients with a score of 1 on the CHA2DS2-VASc.
METHODS: We conducted this retrospective study of 140,420 patients with AF in Swedish nationwide health registries on the basis of varying definitions of "stroke events."
RESULTS: Using a wide "stroke" diagnosis (including hospital discharge diagnoses of ischemic stroke as well as unspecified stroke, transient ischemic attack, and pulmonary embolism) yielded a 44% higher annual risk than if only ischemic strokes were counted. Including stroke events in conjunction with the index hospitalization for AF doubled the long-term risk beyond the first 4 weeks. For women, annual stroke rates varied between 0.1% and 0.2% depending on which event definition was used; for men, the corresponding rates were 0.5% and 0.7%.
CONCLUSIONS: The risk of ischemic stroke in patients with AF and a CHA2DS2-VASc score of 1 seems to be lower than previously reported.
Copyright © 2015 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  epidemiology; oral anticoagulation; stroke

Mesh:

Substances:

Year:  2015        PMID: 25614418     DOI: 10.1016/j.jacc.2014.10.052

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  46 in total

1.  Effectiveness and Safety of Standard-Dose Nonvitamin K Antagonist Oral Anticoagulants and Warfarin Among Patients With Atrial Fibrillation With a Single Stroke Risk Factor: A Nationwide Cohort Study.

Authors:  Gregory Y H Lip; Flemming Skjøth; Peter Brønnum Nielsen; Jette Nordstrøm Kjældgaard; Torben Bjerregaard Larsen
Journal:  JAMA Cardiol       Date:  2017-08-01       Impact factor: 14.676

Review 2.  Cardioembolic Stroke.

Authors:  Hooman Kamel; Jeff S Healey
Journal:  Circ Res       Date:  2017-02-03       Impact factor: 17.367

3.  Clinical Benefit of American College of Chest Physicians Versus European Society of Cardiology Guidelines for Stroke Prophylaxis in Atrial Fibrillation.

Authors:  Ambar A Andrade; Brian F Gage
Journal:  J Gen Intern Med       Date:  2015-10       Impact factor: 5.128

Review 4.  Atrial fibrillation in women: epidemiology, pathophysiology, presentation, and prognosis.

Authors:  Darae Ko; Faisal Rahman; Renate B Schnabel; Xiaoyan Yin; Emelia J Benjamin; Ingrid E Christophersen
Journal:  Nat Rev Cardiol       Date:  2016-04-07       Impact factor: 32.419

Review 5.  Incorporating Stroke and Bleeding Risk Stratification Tools into Atrial Fibrillation Management Making Sense of the Alphabet Soup.

Authors:  Thomas F Deering
Journal:  J Atr Fibrillation       Date:  2017-04-30

6.  Management of Complications in Anticoagulated Patients with Atrial Fibrillation.

Authors:  George D Katritsis; Demosthenes G Katritsis
Journal:  Arrhythm Electrophysiol Rev       Date:  2017-12

Review 7.  Developing a Conversation Aid to Support Shared Decision Making: Reflections on Designing Anticoagulation Choice.

Authors:  Claudia L Zeballos-Palacios; Ian G Hargraves; Peter A Noseworthy; Megan E Branda; Marleen Kunneman; Bruce Burnett; Michael R Gionfriddo; Christopher J McLeod; Haeshik Gorr; Juan Pablo Brito; Victor M Montori
Journal:  Mayo Clin Proc       Date:  2019-01-11       Impact factor: 7.616

8.  Comparison of treatment persistence with different oral anticoagulants in patients with atrial fibrillation.

Authors:  Tomas Forslund; Björn Wettermark; Paul Hjemdahl
Journal:  Eur J Clin Pharmacol       Date:  2015-11-27       Impact factor: 2.953

9.  Individualising Anticoagulant Therapy in Atrial Fibrillation Patients.

Authors:  Marco Alings
Journal:  Arrhythm Electrophysiol Rev       Date:  2016-08

Review 10.  Cardiovascular Care of Masters Athletes.

Authors:  Timothy W Churchill; Aaron L Baggish
Journal:  J Cardiovasc Transl Res       Date:  2020-03-18       Impact factor: 4.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.